Genome-wide transcriptional response of MPP⁺-treated human neuroblastoma SH-SY5Y cells to apomorphine

References

• Agani FH, Pichiule P, Chavez JC, LaManna JC. 2000. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem. 275:35863–35867. doi: 10.1074/jbc.M005643200
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 16:448–458. doi: 10.1002/mds.1090
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Rodolfi G, Landi A, Natuzzi F, Siri C, Pezzoli G. 2011. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 258:579–585. doi: 10.1007/s00415-010-5793-z
   PubMed Web of Science ®Google Scholar
• Bandiera S, Rüberg S, Girard M, Cagnard N, Hanein S, Chrétien D, Munnich A, Lyonnet S, Henrion-Caude A. 2011. Nuclear outsourcing of RNA interference components to human mitochondria. PLoS One. 6:e20746. doi: 10.1371/journal.pone.0020746
   PubMed Web of Science ®Google Scholar
• Carron R, Fraix V, Maineri C, Seigneuret E, Piallat B, Krack P, Pollak P, Benabid AL, Chabardès S. 2011. High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review. J Neural Transm. 118:915–924. doi: 10.1007/s00702-010-0556-7
   PubMed Web of Science ®Google Scholar
• Choi DK, Kim IS, Do JH. 2014. Signaling pathway analysis of MPP+-treated human neuroblastoma SH-SY5Y cells. Biotechnol Bioprocess Eng. 19:332–340. doi: 10.1007/s12257-013-0754-x
   Web of Science ®Google Scholar
• Correia SC, Carvalho C, Cardoso S, Santos RX, Plácido AI, Candeias E, Duarte AI, Moreira PI. 2013. Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: not an “iffy” question! Curr Pharm Des. 19:6809–6822. doi: 10.2174/1381612811319380013
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. 2003. Parkinson’s disease: mechanisms and models. Neuron. 39:889–909. doi: 10.1016/S0896-6273(03)00568-3
   PubMed Web of Science ®Google Scholar
• De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, Morgante L, Mariani CB, Sganzerla E, Pezzoli G, Antonini A. 2006. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatr. 77:450–453. doi: 10.1136/jnnp.2005.078659
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. 2004. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 21:687–709. doi: 10.2165/00002512-200421110-00001
   PubMed Web of Science ®Google Scholar
• Do JH. 2014. Neurotoxin-induced pathway perturbation in human neuroblastoma SH-EP cells. Mol Cells. 37:672–684. doi: 10.14348/molcells.2014.0173
   PubMed Web of Science ®Google Scholar
• Do JH. 2015. Genome-wide transcriptional comparison of MPP+ treated human neuroblastoma cells with the state space model. AIMS Mol Sci. 2:440–460. doi: 10.3934/molsci.2015.4.440
   Google Scholar
• Du P, Kibbe WA, Lin SM. 2008. Lumi: a pipeline for processing Illumina microarray. Bioinformatics. 24:1547–1548. doi: 10.1093/bioinformatics/btn224
   PubMed Web of Science ®Google Scholar
• Gassen M, Glinka Y, Pinchasi B, Youdim MB. 1996. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol. 308:219–225. doi: 10.1016/0014-2999(96)00291-9
   PubMed Web of Science ®Google Scholar
• Grunblatt E, Mandel S, Gassen M, Youdim MB. 1999. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl. 55:57–70.
   PubMedGoogle Scholar
• Hochachka PW, Buck LT, Doll CJ, Land SC. 1996. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA. 93:9493–9498. doi: 10.1073/pnas.93.18.9493
   PubMed Web of Science ®Google Scholar
• Hung JH. 2013. Gene set/pathway enrichment analysis. Methods Mol Biol. 939:201–213. doi: 10.1007/978-1-62703-107-3_13
   PubMedGoogle Scholar
• Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. 2012. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40:D109–D114. doi: 10.1093/nar/gkr988
   PubMed Web of Science ®Google Scholar
• Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK. 2009. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem. 284:299065–29076.
   Google Scholar
• LeWitt PA. 2004. Subcutaneously administered apomorphine: Pharmacokinetics and metabolism. Neurology. 62:S8–S11. doi: 10.1212/WNL.62.6_suppl_4.S8
   Google Scholar
• Ma L, Ohyagi Y, Nakamura N, Iinuma KM, Miyoshi K, Himeno E, Soejima N, Yanagihara YT, Sakae N, Yamasaki R, Kira J. 2011. Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine. J Alzheimers Dis. 27:225–237.
   PubMed Web of Science ®Google Scholar
• Maglott D, Ostell J, Pruitt KD, Tatusova T. 2011. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 39:D52–D57. doi: 10.1093/nar/gkq1237
   PubMedGoogle Scholar
• Marsden CD, Parkes JD, Quinn N. 1981. Fluctuations and disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S, editors. Neurology 2: movement disorders. London: Butterworth Scientific; p. 96–122.
   Google Scholar
• Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 303:791–804. doi: 10.1124/jpet.102.039867
   PubMed Web of Science ®Google Scholar
• Muguet D, Broussolle E, Chazot G. 1995. Apomorphine in patients with Parkinson’s disease. Biomed Pharmacother. 49:197–209. doi: 10.1016/0753-3322(96)82620-5
   PubMed Web of Science ®Google Scholar
• Nicklas WJ, Vyas I, Heikkila RE. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-mehthyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:2503–2508. doi: 10.1016/0024-3205(85)90146-8
   PubMed Web of Science ®Google Scholar
• Okun MS, Foote KD. 2010. Parkinson’s disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother. 10:1847–1857. doi: 10.1586/ern.10.156
   PubMed Web of Science ®Google Scholar
• Ramsay RE, Singer RP. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondria. J Biol Chem. 75:7585–7587.
   Google Scholar
• Ribarič S. 2012. The pharmacological properties and therapeutic use of apomorphine. Molecules. 17:5289–5309. doi: 10.3390/molecules17055289
   PubMed Web of Science ®Google Scholar
• Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, et al. 2005. Hypoxia-induced factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem. 280:41732–41743. doi: 10.1074/jbc.M504963200
   PubMed Web of Science ®Google Scholar
• Sydow O. 2008. Parkinson’s disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. FEBS J. 275:1370–1376. doi: 10.1111/j.1742-4658.2008.06295.x
   PubMed Web of Science ®Google Scholar
• Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116–5121. doi: 10.1073/pnas.091062498
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. 1993. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 82:3610–3615.
   PubMed Web of Science ®Google Scholar
• Williams ZR, Goodman CB, Soliman KF. 2007. Anaerobic glycolysis protection against 1-methyl-4-phenyl-pyridinium (MPP+) toxicity in C6 glioma cells. Neurochem Res. 32:1071–1080. doi: 10.1007/s11064-006-9276-7
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. 2012. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 16:284–287. doi: 10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Zhang JD, Wiemann S. 2009. KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor. Bioinformatics. 25:1470–1471. doi: 10.1093/bioinformatics/btp167
   PubMed Web of Science ®Google Scholar